Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330070 · ClinicalTrials.gov registry record · Phase 2
Control of Asthma Patients Symptomatic on Inhaled Corticosteroids
A Phase 2 study of Asthma, sponsored by Inflazyme Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 8
- Study locations
NCT00330070: Completed Phase 2 study of Asthma, sponsored by Inflazyme Pharmaceuticals.
NCT00330070 is a Phase 2 study of Asthma that has completed, run by Inflazyme Pharmaceuticals. The registered enrollment target is 200 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00330070, a Phase 2 study of Asthma, has completed, sponsored by Inflazyme Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of the study is to determine whether IPL512,602 is safe and effective for the treatment of asthma symptoms in patients who remain symptomatic on a background therapy of inhaled corticosteroids.
Conditions Studied
Interventions
- DRUG IPL512,602 20 mg once daily
- DRUG IPL512,602 Matching Placebo once daily
Study Locations (8)
California
- West Coast Clinical Trials - Long Beach
- Allergy Research Foundation, Inc. - Los Angeles
- Asthma Medical Group & Resarch - San Diego
- San Jose Clinical Research - San Jose
Oregon
- Clinical Research Institute of South Oregaon - Medford
- Allergy Associates Research Center - Portland
Massachusetts
- Northeast Medical Research Associates, Inc - No. Dartmouth
Wisconsin
- University of Wisconsin - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00330070 record still lists
NCT00330070 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which IPL512,602 20 mg once daily is the first listed.
NCT00330070 lists 8 locations in 4 states (California, Oregon, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00330070 about?
NCT00330070 is a clinical study titled "Control of Asthma Patients Symptomatic on Inhaled Corticosteroids". The purpose of the study is to determine whether IPL512,602 is safe and effective for the treatment of asthma symptoms in patients who remain symptomatic on a background therapy of inhaled corticosteroids.
What is the current status of trial NCT00330070?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2006-05. Estimated completion is 2007-01.
What conditions does trial NCT00330070 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00330070?
The interventions under investigation include: IPL512,602 20 mg once daily (DRUG), IPL512,602 Matching Placebo once daily (DRUG).
Who is sponsoring clinical trial NCT00330070?
This trial is sponsored by Inflazyme Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00330070 being conducted?
This trial has 8 study locations across California, Massachusetts, Oregon, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00330070's enrollment target sits among peer trials
200 162nd of 374 higher than 210 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia